Face validity expressed as residual disease activity in the presence of remission*
| TJC28 | SJC28 | CRP | PhGA | PtGA | Pain | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candidate remission definition | 90% | Max | 90% | Max | 90% | Max | 90% | Max | 90% | Max | 90% | Max |
| TJC28, SJC28, CRP ≤1 | 1 | 1 | 1 | 1 | 0.6 | 1 | 2 | 6 | 4 | 8 | 4 | 8 |
| TJC28, SJC28, CRP, PhGA ≤1 | 1 | 1 | 1 | 1 | 0.6 | 1 | 1 | 1 | 2 | 7 | 2 | 8 |
| TJC28, SJC28, CRP, PtGA ≤1 | 1 | 1 | 1 | 1 | 0.6 | 1 | 2 | 2 | 1 | 1 | 2 | 3 |
| TJC28, SJC28, CRP, pain ≤1 | 1 | 1 | 1 | 1 | 0.6 | 1 | 2 | 4 | 2 | 6 | 1 | 1 |
| TJC28, SJC28, CRP, PhGA, PtGA ≤1 | 1 | 1 | 1 | 1 | 0.7 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| TJC28, SJC28, CRP, PhGA, pain ≤1 | 1 | 1 | 1 | 1 | 0.7 | 1 | 1 | 1 | 1 | 5 | 1 | 1 |
| TJC28, SJC28, CRP, PtGA, pain ≤1 | 1 | 1 | 1 | 1 | 0.7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| TJC28, SJC28, CRP, PhGA, PtGA, pain ≤1 | 1 | 1 | 1 | 1 | 0.7 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| DAS28 <2.6 | 2 | 7 | 4 | 21 | 0.7 | 2.5 | 2 | 5 | 3 | 8 | 2 | 10 |
| DAS28 <2.0 | 0 | 3 | 2 | 6 | 0.7 | 2.5 | 2 | 3 | 2 | 4 | 2 | 4 |
| SDAI ≤3.3 | 1 | 2 | 1 | 2 | 0.7 | 2.7 | 2 | 2 | 1 | 2 | 1 | 3 |
↵* Values are the upper limits of residual disease activity in the RA core set measures for candidate definitions of remission observed in trial data sets using all trial arms (methotrexate monotherapy, tumor necrosis factor inhibitor monotherapy, and combination therapy with tumor necrosis factor inhibitors plus methotrexate). CRP is in mg/dl.
90% = 90th percentile; Max = maximum observed value; DAS28 = 28-joint Disease Activity
Score; SDAI = Simplified Disease Activity Index (see table 1 for other definitions).